BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5,106 | $6,572 | $1,124 | $2,408 |
| - Cash | $681 | $376 | $377 | $394 |
| + Debt | $1,731 | $1,740 | $1,724 | $1,726 |
| Enterprise Value | $6,155 | $7,936 | $2,471 | $3,740 |
| Revenue | $222 | $9 | $78 | $70 |
| % Growth | 2,285.3% | -88% | 11.4% | – |
| Gross Profit | $218 | $7 | $74 | $67 |
| % Margin | 98.3% | 73.7% | 95.6% | 95.5% |
| EBITDA | -$437 | -$565 | -$397 | -$534 |
| % Margin | -196.9% | -6,078.3% | -511.9% | -765.7% |
| Net Income | -$536 | -$643 | -$481 | -$563 |
| % Margin | -241.4% | -6,913.9% | -619.7% | -806.9% |
| EPS Diluted | -2.88 | -3.95 | -3.35 | -4.43 |
| % Growth | 27.1% | -17.9% | 24.4% | – |
| Operating Cash Flow | -$521 | -$528 | -$419 | -$498 |
| Capital Expenditures | -$1 | -$1 | -$6 | -$48 |
| Free Cash Flow | -$522 | -$529 | -$426 | -$546 |